Organization: AstraZeneca Pharma India Ltd
MD: Mr Sanjay Murdeshwar
Bioscience Revenue: Rs 468.13 crore
AstraZeneca (AZ) Pharma India reported total business of Rs 468.13 crore for the 12-month period ending March 31, 2015. AZ registered six percent growth in bioscience revenue. The primary business here includes manufacture and sale of pharma products, clinical trial services, and copromotional services. AZ rendered co-promotion services for pharmaceutical products to Bristol Myers Squibb (BMS) India till January 31, 2014. AstraZeneca group companies also acquired the global diabetic business of BMS.
Consequent to the aforesaid acquisition, AZ has entered into a consignment sale agreement with BMS and accordingly sale of diabetic products by BMS in India for the period February 1, 2014 to March 31,2014, has been included as part of the sales of the company.
AZ and Dr Reddy's Laboratories (DRL) entered into a distribution agreement for two drugs namely, Riax and Riax-M. The drugs' trademarks are with AstraZeneca group. DRL will distribute the two drugs in the country.
It also announced its collaboration with Sun Pharmaceutical Industries in June 2015. They entered into a distribution services agreement for AZ's brand ‘Axcer', a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS) in India.